Research Paper Volume 11, Issue 24 pp 12032—12042

Compound 13 activates AMPK-Nrf2 signaling to protect neuronal cells from oxygen glucose deprivation-reoxygenation

Figure 1. Compound 13 protected SH-SY5Y neuronal cells and primary neurons from OGD-R. The structure of C13 is shown in (A). SH-SY5Y human neuronal cells (B and C) or the primary murine hippocampal neurons (D and E) were treated with applied concentration (1–25 μM) of compound 13 (“C13”), together with/out OGD exposure for 4h, followed by 48h re-oxygenation (“OGD-R”), cell viability was tested by CCK-8 assay (B and D); Cell death was examined by medium LDH release assay (C and E). “OGD-R” stands for OGD/re-oxygenation (Same for all figures). “Mock” stands for Mock control cells (no OGD-R, same for all Figures). “Vehicle” stands for the vehicle for C13 (0.1% DMSO, same for all Figures). For the OGD-R experiments, neuronal cells were always pretreated with C13 for 2h before OGD (Same for all figures). Bars stands for mean ± standard deviation (SD, n=5). * p<0.05 vs. “Mock” cells. #p<0.05 vs. cells with “OGD-R” treatment (no C13 pretreatment). Each experiment was repeated four times with similar results obtained.